Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T16:41:36.564Z.
Calculation as of: 2026-10-06T16:41:36.564Z.
Quote observation: 2026-10-06T16:40:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bae8dd55c1776b4784265b7d6b815fecf0da21712464e51122872d0292d60ac3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$3.51B
Price/OCF Ratio
N/A
TTM Avg
11.75
3Y Avg
11.73
5Y Avg
11.73
Market Cap
$3.54B
Price/OCF Ratio
41.17
TTM Avg
62.20
3Y Avg
178.64
5Y Avg
178.64
Market Cap
$3.53B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.41B
Price/OCF Ratio
17.53
TTM Avg
27.05
3Y Avg
38.50
5Y Avg
38.50
Market Cap
$3.11B
Price/OCF Ratio
N/A
TTM Avg
16.06
3Y Avg
20.39
5Y Avg
20.39
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Celcuity Inc. (CELC) | $3.50B | N/A | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.51B | N/A | 11.75 | 11.73 | 11.73 |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.54B | 41.17 | 62.20 | 178.64 | 178.64 |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.53B | N/A | N/A | N/A | N/A |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.41B | N/A | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.41B | 17.53 | 27.05 | 38.50 | 38.50 |
| CareDx, Inc (CDNA)vs › | $3.40B | 36.29 | 25.34 | 102.30 | 213.86 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.34B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.11B | N/A | 16.06 | 20.39 | 20.39 |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.05B | 77.69 | 106.08 | 106.08 | 106.08 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
